Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Current Leases (2019 - 2025)

Denali Therapeutics (DNLI) has disclosed Current Leases for 7 consecutive years, with $9.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Leases rose 14.04% to $9.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $9.2 million, a 14.04% increase, with the full-year FY2024 number at $8.3 million, up 14.44% from a year prior.
  • Current Leases was $9.2 million for Q3 2025 at Denali Therapeutics, up from $8.9 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $9.2 million in Q3 2025 to a low of $4.9 million in Q1 2021.
  • A 5-year average of $7.0 million and a median of $7.1 million in 2022 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: soared 34.58% in 2022, then dropped 0.79% in 2023.
  • Denali Therapeutics' Current Leases stood at $5.5 million in 2021, then skyrocketed by 34.2% to $7.3 million in 2022, then dropped by 0.79% to $7.3 million in 2023, then grew by 14.44% to $8.3 million in 2024, then rose by 10.3% to $9.2 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Current Leases are $9.2 million (Q3 2025), $8.9 million (Q2 2025), and $8.6 million (Q1 2025).